Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy

Dalil Hannani, Antonella Sistigu, Oliver Kepp, Lorenzo Galluzzi, Guido Kroemer, Laurence Zitvogel

Research output: Contribution to journalArticle

Abstract

For a long time, anticancer therapies were believed to work (and hence convey a therapeutic benefit) either by killing cancer cells or by inducing a permanent arrest in their cell cycle (senescence). In both scenarios, the efficacy of anticancer regimens was thought to depend on cancer cell-intrinsic features only. More recently, the importance of the tumor microenvironment (including stromal and immune cells) has been recognized, along with the development of therapies that function by modulating tumor cell-extrinsic pathways. In particular, it has been shown that some chemotherapeutic and radiotherapeutic regimens trigger cancer cell death while stimulating an active immune response against the tumor. Such an immunogenic cell death relies on the coordinated emission of specific signals from dying cancer cells and their perception by the host immune system. The resulting tumor-specific immune response is critical for the eradication of tumor cells that may survive therapy. In this review, we discuss the molecular mechanisms that underlie the vaccine-like effects of some chemotherapeutic and radiotherapeutic regimens, with particular attention to the signaling pathways and genetic elements that constitute the prerequisites for immunogenic anticancer therapy.

Original languageEnglish
Pages (from-to)351-358
Number of pages8
JournalCancer Journal (United States)
Volume17
Issue number5
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Radiotherapy
Vaccines
Drug Therapy
Neoplasms
Cell Death
Active Immunity
Therapeutics
Tumor Microenvironment
Cell Aging
Stromal Cells
Immune System
Cell Cycle

Keywords

  • ATP
  • Calreticulin
  • dendritic cells
  • HMGB1
  • NLRP3
  • TLR4

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011). Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer Journal (United States), 17(5), 351-358. https://doi.org/10.1097/PPO.0b013e3182325d4d

Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. / Hannani, Dalil; Sistigu, Antonella; Kepp, Oliver; Galluzzi, Lorenzo; Kroemer, Guido; Zitvogel, Laurence.

In: Cancer Journal (United States), Vol. 17, No. 5, 09.2011, p. 351-358.

Research output: Contribution to journalArticle

Hannani, D, Sistigu, A, Kepp, O, Galluzzi, L, Kroemer, G & Zitvogel, L 2011, 'Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy', Cancer Journal (United States), vol. 17, no. 5, pp. 351-358. https://doi.org/10.1097/PPO.0b013e3182325d4d
Hannani, Dalil ; Sistigu, Antonella ; Kepp, Oliver ; Galluzzi, Lorenzo ; Kroemer, Guido ; Zitvogel, Laurence. / Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. In: Cancer Journal (United States). 2011 ; Vol. 17, No. 5. pp. 351-358.
@article{728e6a2c4607402c834e7357e93d5f7e,
title = "Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy",
abstract = "For a long time, anticancer therapies were believed to work (and hence convey a therapeutic benefit) either by killing cancer cells or by inducing a permanent arrest in their cell cycle (senescence). In both scenarios, the efficacy of anticancer regimens was thought to depend on cancer cell-intrinsic features only. More recently, the importance of the tumor microenvironment (including stromal and immune cells) has been recognized, along with the development of therapies that function by modulating tumor cell-extrinsic pathways. In particular, it has been shown that some chemotherapeutic and radiotherapeutic regimens trigger cancer cell death while stimulating an active immune response against the tumor. Such an immunogenic cell death relies on the coordinated emission of specific signals from dying cancer cells and their perception by the host immune system. The resulting tumor-specific immune response is critical for the eradication of tumor cells that may survive therapy. In this review, we discuss the molecular mechanisms that underlie the vaccine-like effects of some chemotherapeutic and radiotherapeutic regimens, with particular attention to the signaling pathways and genetic elements that constitute the prerequisites for immunogenic anticancer therapy.",
keywords = "ATP, Calreticulin, dendritic cells, HMGB1, NLRP3, TLR4",
author = "Dalil Hannani and Antonella Sistigu and Oliver Kepp and Lorenzo Galluzzi and Guido Kroemer and Laurence Zitvogel",
year = "2011",
month = "9",
doi = "10.1097/PPO.0b013e3182325d4d",
language = "English",
volume = "17",
pages = "351--358",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "5",

}

TY - JOUR

T1 - Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy

AU - Hannani, Dalil

AU - Sistigu, Antonella

AU - Kepp, Oliver

AU - Galluzzi, Lorenzo

AU - Kroemer, Guido

AU - Zitvogel, Laurence

PY - 2011/9

Y1 - 2011/9

N2 - For a long time, anticancer therapies were believed to work (and hence convey a therapeutic benefit) either by killing cancer cells or by inducing a permanent arrest in their cell cycle (senescence). In both scenarios, the efficacy of anticancer regimens was thought to depend on cancer cell-intrinsic features only. More recently, the importance of the tumor microenvironment (including stromal and immune cells) has been recognized, along with the development of therapies that function by modulating tumor cell-extrinsic pathways. In particular, it has been shown that some chemotherapeutic and radiotherapeutic regimens trigger cancer cell death while stimulating an active immune response against the tumor. Such an immunogenic cell death relies on the coordinated emission of specific signals from dying cancer cells and their perception by the host immune system. The resulting tumor-specific immune response is critical for the eradication of tumor cells that may survive therapy. In this review, we discuss the molecular mechanisms that underlie the vaccine-like effects of some chemotherapeutic and radiotherapeutic regimens, with particular attention to the signaling pathways and genetic elements that constitute the prerequisites for immunogenic anticancer therapy.

AB - For a long time, anticancer therapies were believed to work (and hence convey a therapeutic benefit) either by killing cancer cells or by inducing a permanent arrest in their cell cycle (senescence). In both scenarios, the efficacy of anticancer regimens was thought to depend on cancer cell-intrinsic features only. More recently, the importance of the tumor microenvironment (including stromal and immune cells) has been recognized, along with the development of therapies that function by modulating tumor cell-extrinsic pathways. In particular, it has been shown that some chemotherapeutic and radiotherapeutic regimens trigger cancer cell death while stimulating an active immune response against the tumor. Such an immunogenic cell death relies on the coordinated emission of specific signals from dying cancer cells and their perception by the host immune system. The resulting tumor-specific immune response is critical for the eradication of tumor cells that may survive therapy. In this review, we discuss the molecular mechanisms that underlie the vaccine-like effects of some chemotherapeutic and radiotherapeutic regimens, with particular attention to the signaling pathways and genetic elements that constitute the prerequisites for immunogenic anticancer therapy.

KW - ATP

KW - Calreticulin

KW - dendritic cells

KW - HMGB1

KW - NLRP3

KW - TLR4

UR - http://www.scopus.com/inward/record.url?scp=80053353709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053353709&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3182325d4d

DO - 10.1097/PPO.0b013e3182325d4d

M3 - Article

C2 - 21952286

AN - SCOPUS:80053353709

VL - 17

SP - 351

EP - 358

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 5

ER -